{"id":30326,"date":"2022-06-27T13:09:00","date_gmt":"2022-06-27T05:09:00","guid":{"rendered":"https:\/\/flcube.com\/?p=30326"},"modified":"2025-03-25T13:13:40","modified_gmt":"2025-03-25T05:13:40","slug":"genor-biopharma-and-abogen-biosciences-collaborate-on-cancer-mrna-therapies","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=30326","title":{"rendered":"Genor Biopharma and Abogen Biosciences Collaborate on Cancer mRNA Therapies"},"content":{"rendered":"\n

China’s Genor Biopharma Co., Ltd (HKG: 6998<\/a>) has entered into a co-development agreement with compatriot firm Abogen Biosciences Co., Ltd, a Suzhou-based mRNA drug developer. The collaboration aims to develop mRNA medicines against cancer by integrating Genor’s biologic antibody development platform with Abogen’s mRNA technology platform.<\/p>\n\n\n\n

Collaboration Details<\/strong>
The partnership combines Genor’s first-in-class\/best-in-class immuno-oncology bispecific\/multi-specific antibody R&D platform with Abogen’s mRNA expertise. Genor has initiated multiple molecule discovery programs, while Abogen is known for China’s first home-grown COVID-19 mRNA vaccine, developed with the Academy of Military Sciences and Walvax Biotechnology Co., Ltd. Abogen secured clinical trial approval for the vaccine in June 2020, and it is currently in Phase III trials with a manufacturing license awarded in November last year.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

China’s Genor Biopharma Co., Ltd (HKG: 6998) has entered into a co-development agreement with compatriot…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[2552,424,953,63],"class_list":["post-30326","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-abogen-biosciences","tag-genor-biopharma","tag-hkg-6998","tag-mrna"],"yoast_head":"\nGenor Biopharma and Abogen Biosciences Collaborate on Cancer mRNA Therapies - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China's Genor Biopharma Co., Ltd (HKG: 6998) has entered into a co-development agreement with compatriot firm Abogen Biosciences Co., Ltd, a Suzhou-based mRNA drug developer. The collaboration aims to develop mRNA medicines against cancer by integrating Genor's biologic antibody development platform with Abogen's mRNA technology platform.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=30326\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Genor Biopharma and Abogen Biosciences Collaborate on Cancer mRNA Therapies\" \/>\n<meta property=\"og:description\" content=\"China's Genor Biopharma Co., Ltd (HKG: 6998) has entered into a co-development agreement with compatriot firm Abogen Biosciences Co., Ltd, a Suzhou-based mRNA drug developer. The collaboration aims to develop mRNA medicines against cancer by integrating Genor's biologic antibody development platform with Abogen's mRNA technology platform.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=30326\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2022-06-27T05:09:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-03-25T05:13:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30326#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30326\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Genor Biopharma and Abogen Biosciences Collaborate on Cancer mRNA Therapies\",\"datePublished\":\"2022-06-27T05:09:00+00:00\",\"dateModified\":\"2025-03-25T05:13:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30326\"},\"wordCount\":142,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Abogen Biosciences\",\"Genor Biopharma\",\"HKG: 6998\",\"mRNA\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=30326#respond\"]}],\"copyrightYear\":\"2022\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30326\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=30326\",\"name\":\"Genor Biopharma and Abogen Biosciences Collaborate on Cancer mRNA Therapies - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2022-06-27T05:09:00+00:00\",\"dateModified\":\"2025-03-25T05:13:40+00:00\",\"description\":\"China's Genor Biopharma Co., Ltd (HKG: 6998) has entered into a co-development agreement with compatriot firm Abogen Biosciences Co., Ltd, a Suzhou-based mRNA drug developer. The collaboration aims to develop mRNA medicines against cancer by integrating Genor's biologic antibody development platform with Abogen's mRNA technology platform.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30326#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=30326\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30326#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Genor Biopharma and Abogen Biosciences Collaborate on Cancer mRNA Therapies\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Genor Biopharma and Abogen Biosciences Collaborate on Cancer mRNA Therapies - Insight, China's Pharmaceutical Industry","description":"China's Genor Biopharma Co., Ltd (HKG: 6998) has entered into a co-development agreement with compatriot firm Abogen Biosciences Co., Ltd, a Suzhou-based mRNA drug developer. The collaboration aims to develop mRNA medicines against cancer by integrating Genor's biologic antibody development platform with Abogen's mRNA technology platform.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=30326","og_locale":"en_US","og_type":"article","og_title":"Genor Biopharma and Abogen Biosciences Collaborate on Cancer mRNA Therapies","og_description":"China's Genor Biopharma Co., Ltd (HKG: 6998) has entered into a co-development agreement with compatriot firm Abogen Biosciences Co., Ltd, a Suzhou-based mRNA drug developer. The collaboration aims to develop mRNA medicines against cancer by integrating Genor's biologic antibody development platform with Abogen's mRNA technology platform.","og_url":"https:\/\/flcube.com\/?p=30326","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2022-06-27T05:09:00+00:00","article_modified_time":"2025-03-25T05:13:40+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=30326#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=30326"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Genor Biopharma and Abogen Biosciences Collaborate on Cancer mRNA Therapies","datePublished":"2022-06-27T05:09:00+00:00","dateModified":"2025-03-25T05:13:40+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=30326"},"wordCount":142,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Abogen Biosciences","Genor Biopharma","HKG: 6998","mRNA"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=30326#respond"]}],"copyrightYear":"2022","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=30326","url":"https:\/\/flcube.com\/?p=30326","name":"Genor Biopharma and Abogen Biosciences Collaborate on Cancer mRNA Therapies - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2022-06-27T05:09:00+00:00","dateModified":"2025-03-25T05:13:40+00:00","description":"China's Genor Biopharma Co., Ltd (HKG: 6998) has entered into a co-development agreement with compatriot firm Abogen Biosciences Co., Ltd, a Suzhou-based mRNA drug developer. The collaboration aims to develop mRNA medicines against cancer by integrating Genor's biologic antibody development platform with Abogen's mRNA technology platform.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=30326#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=30326"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=30326#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Genor Biopharma and Abogen Biosciences Collaborate on Cancer mRNA Therapies"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/30326","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=30326"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/30326\/revisions"}],"predecessor-version":[{"id":30327,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/30326\/revisions\/30327"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=30326"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=30326"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=30326"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}